|
|
| | Edasalonexent Basic information |
| Product Name: | Edasalonexent | | Synonyms: | Edasalonexent;2-amino-N-(2-((4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)benzamide;CAT1004;CAT-1004;Benzamide, 2-hydroxy-N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl]amino]ethyl]- | | CAS: | 1204317-86-1 | | MF: | C31H42N2O3 | | MW: | 490.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1204317-86-1.mol |  |
| | Edasalonexent Chemical Properties |
| Boiling point | 716.8±60.0 °C(Predicted) | | density | 1.031±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 120 mg/mL (244.56 mM) | | form | Oil | | pka | 8.46±0.30(Predicted) | | color | Light yellow to yellow |
| | Edasalonexent Usage And Synthesis |
| Uses | Edasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor. | | in vivo | The treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury[1]. | | References | [1] Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341. DOI:10.1172/jci.insight.90341
[2] Donovan JM, et al. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol DOI:10.1002/jcph.842 |
| | Edasalonexent Preparation Products And Raw materials |
|